Date: 2013-10-21
Type of information: R&D agreement
Compound: compounds and targets with novel mechanisms that have disease-modifying potential for the treatment of chronic kidney disease
Company: Evotec (Germany) AstraZeneca (UK)
Therapeutic area: Kidney diseases - Renal diseases
Type agreement: R&D
development
licensing
commercialisation
Action mechanism:
Disease: chronic kidney disease
Details: * On October 21, 2013, Evotec has announced that it has signed an agreement with AstraZeneca in the field of kidney diseases. Initial focus of the alliance will be exploring compounds and targets with novel mechanisms that have disease-modifying potential for the treatment of chronic kidney disease. Under the terms of this licence and collaboration agreement, AstraZeneca will receive access to a selected series of molecules identified in a screening effort, which is part of Evotec’s systematic kidney disease initiative. This particular programme has been designed to explore a key mechanism in the field of chronic kidney disease. AstraZeneca will provide industrial scope and scale as well as pharmaceutical development expertise and marketing capabilities.
Financial terms: The agreement between Evotec and AstraZeneca triggers an undisclosed upfront payment as well as pre-clinical, clinical and regulatory milestones. Evotec is also eligible for additional milestone and royalty payments related to commercialisation. Evotec will receive research funding for work that will be conducted in collaboration with AstraZeneca. Specific financial details were not disclosed.
Latest news:
